Study results reveal that KRAS G12C mutations vary according to sex and ethnicity in patients with cancer. Read More ›

Researchers reported that molecular testing in patients with non–small-cell lung cancer aged ≥70 years is performed at the same proportions as in younger patients. Read More ›

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates in patients with lung cancer revealed a correlation with clinical characteristics that may have a significant effect on personalized cancer treatment. Read More ›

A recently released report indicates that low-dose computed tomography targeted screening for lung cancer confers patient health and public health benefits. Read More ›

A large cohort analysis of treatment status, treatment regimen, and outcomes in patients with KRAS-mutated advanced NSCLC revealed valuable information for future clinical trials. Read More ›

Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. Read More ›

In recently released study results of the phase 2 CodeBreaK 100 trial, sotorasib demonstrated a response rate across all trial subgroups. Read More ›

Lung cancer incidence rates have declined due to a decrease in risk factors and improved screening and treatment. Read More ›

Immune checkpoint inhibitors cause rare severe adverse events in patients, but most patients improve with treatment. Read More ›

Patients with NSCLC harboring KRAS G12C have distinct imaging patterns from patients with other NSCLC genetic mutations. Read More ›